Comparable Immune Alterations and Inflammatory Signatures in ME/CFS and Long COVID
- PMID: 41463013
- PMCID: PMC12730569
- DOI: 10.3390/biomedicines13123001
Comparable Immune Alterations and Inflammatory Signatures in ME/CFS and Long COVID
Abstract
Background: Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a debilitating condition characterized by persistent fatigue and multisystemic symptoms, such as cognitive impairment, musculoskeletal pain, and post-exertional malaise. Recently, parallels have been drawn between ME/CFS and Long COVID, a post-viral syndrome following infection with SARS-CoV-2, which shares many clinical features with CFS. Both conditions involve chronic immune activation, raising questions about their immunopathological overlap. Objectives: This study aimed to compare immune biomarkers between patients with ME/CFS or Long COVID and healthy controls to explore shared immune dysfunction. Methods: We analyzed lymphocyte subsets, cytokine profiles, psychological status and their correlations in 190 participants, 65 with CFS, 54 with Long COVID, and 70 healthy controls. Results: When compared to healthy subjects, results in both conditions were marked by lower levels of lymphocytes (CFS-2.472 × 109/L, p = 0.006, LC-2.051 × 109/L, p = 0.009), CD8+ T cells (CFS-0.394 × 109/L, p = 0.001, LC-0.404 × 109/L, p = 0.001), and NK cells (CFS-0.205 × 109/L, p = 0.001, LC-0.180 × 109/L, p = 0.001), and higher levels of proinflammatory cytokines such as IL-6 (CFS-3.35 pg/mL, p = 0.050 LC-4.04 pg/mL, p = 0.001), TNF (CFS-2.64 pg/mL, p = 0.023, LC-2.50 pg/mL, p = 0.025), IL-4 (CFS-3.72 pg/mL, p = 0.041, LC-3.45 pg/mL, p = 0.048), and IL-10 (CFS-2.29 pg/mL, p = 0.039, LC-2.25 pg/mL, p = 0.018). Conclusions: Notably, there were no significant differences between CFS and Long COVID patients in the tested biomarkers. These results demonstrate that ME/CFS and Long COVID display comparable immune and inflammatory profiles, with no significant biomarker differences observed between the two groups.
Keywords: COVID-19; chronic fatigue; chronic fatigue syndrome; long COVID.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med. Virol. 2021;93:1449–1458. doi: 10.1002/jmv.26424. - DOI - PMC - PubMed
-
- Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. The Lancet Gastroenterol. Hepatol. 2020;5:667–678. doi: 10.1016/S2468-1253(20)30126-6. Erratum in The Lancet Gastroenterol. Hepatol. 2025, 5, e6. https://doi.org/10.1016/S2468-1253(20)30160-6 . - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
